Result: Risk Minimisation Materials for medicines starting with the letter I

Ibandronic acid

Accord-UK Ltd

Ibandronic Acid - Patient Reminder Card

This reminder card contains important safety information that you need to be aware of before and during treatment with Ibandronic acid Actavis 3mg Solution for Injection for treatment of osteoporosis in postmenopausal women at increased risk of fracture

Iclusig

Incyte Biosciences UK Ltd

Iclusig (ponatinib): Important Safety Information for Healthcare Professionals

As part of the terms of the Marketing Authorisation for Iclusig, Incyte Biosciences (UK) Ltd are required to ensure that all Healthcare Professionals who are likely to treat patients with ponatinib are provided with risk minimisation materials. This document contains key information to help identify patients eligible for therapy, understand how ponatinib should be used safely, the risks for patients and the important adverse reactions for which monitoring and dose adjustment are recommended (pancreatitis, increased amylase and lipase levels, myelosuppression, liver function test abnormalities, haemorrhage, cardiac failure/left ventricular dysfunction, arterial occlusion and venous thromboembolism events and hypertension). If you require further information about ponatinib, please consult the SmPC for Iclusig available on www.ema.europa.eu or contact Incyte Biosciences (UK) Ltd on the EU universal free telephone number 00800 00027423.

For Healthcare Professionals

Ilaris

Novartis Pharmaceuticals UK Ltd

Ilaris - Important information for patients with Gouty Arthritis

Patient alert card listing important information to consider before and during treatment with canakinumab for patients with Gouty Arthritis

Ilaris - Important information for patients with Period Fever Syndromes

Patient alert card listing important information to consider before and during treatment with canakinumab for patients with Periodic Fever Syndromes CAPS, TRAPS, HIDS/MKD or FMF

Ilaris - Important information for the patient with Still's Disease (including Adult Onset Still's Disease) and Systemic Juvenile Idiopathic Arthritis

Patient alert card listing important information to consider before and during treatment with canakinumab for patients with Still's Disease (including Adult Onset Still's Disease) and Systemic Juvenile Idiopathic Arthritis

Iluvien

Alimera Sciences Limited

ILUVIEN® Administration Guide

Guidance on the administration technique and details of important adverse events

For Healthcare Professionals

Imlygic

Amgen Ltd

IMLYGIC Information for Patients and Close Contacts

This brochure contains important safety information you should know before and during IMLYGIC treatment. Please read this information carefully before and after each treatment. Please also read the IMLYGIC Package Leaflet. To request a copy of this guide, please contact Amgen Medical Information on +44 (0) 1223 436441

IMLYGIC Patient Alert Card

This IMLYGIC patient alert card includes contact details of the IMLYGIC prescriber, treatment start date, IMLYGIC batch number and information on the potential development of herpetic lesions and the importance of reporting ADRs. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441

IMLYGIC Physician's Brochure

This educational brochure contains important information regarding the risks of transmission and herpetic complications, and safe use and handling of IMLYGIC.This brochure does not contain a comprehensive description of the risks associated with IMLYGIC. Please read the current Summary of Product Characteristics (SmPC) for IMLYGIC. To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441

For Healthcare Professionals

Increlex

Ipsen Ltd

Increlex Dosing Guide

How to use Increlex in the treatment of severe primary IGF-1 deficiency

For Healthcare Professionals

Increlex Patient Leaflet

Patient information about severe primary IGF-1 deficiency and how Increlex can help

Increlex Physician Leaflet

Introduction to Increlex and information on how to administer the product and safety issues relating to use

For Healthcare Professionals

Instanyl

Takeda UK Ltd

Instanyl (fentanyl citrate) 100 mcg Dose Monitoring Card

To be provided to patients receiving treatment with Instanyl by a HCP

Instanyl (fentanyl citrate) 200 mcg Dose Monitoring Card

To be provided to patients receiving treatment with Instanyl by a HCP

Instanyl (fentanyl citrate) 50mcg Dose Monitoring Card

To be provided to patients receiving treatment with Instanyl by a HCP

Instanyl (fentanyl citrate) Multi Dose Patient Guide

To be provided to patients receiving treatment with Instanyl by a HCP

Instanyl (fentanyl citrate) Nasal Spray Information for Pharmacists

Information leaflet for Pharmacists Administering Instanyl

For Healthcare Professionals

Instanyl (fentanyl citrate) Nasal Spray Information for Physicians

Information leaflet for Physicians Administering Instanyl

For Healthcare Professionals

Instanyl (fentanyl citrate) Single Dose Patient Guide

To be provided to patients receiving treatment with Instanyl by a HCP

Isotretinoin

Ranbaxy (UK) Limited a Sun Pharmaceutical Company

Checklist for Prescribing to Female Patients

This material is provided by Ranbaxy UK Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan. This checklist should be completed by the prescriber prior to initiating therapy with Isotretinoin.

For Healthcare Professionals

Contraception Advice for People Taking Isotretinoin

This material is provided by Ranbaxy UK Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan. This brochure should only be given to patients who have been prescribed Isotretinoin. This brochure discusses the different types of contraception, how to use them and how effective they are.

Isotretinoin Patient Information Booklet

This material is provided by Ranbaxy UK Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan. This booklet should be given to patients who have been prescribed Isotretinoin and it describes some of the important facts about Isotretinoin that you need to be aware of.

Pharmacist’s Guide to Dispensing Isotretinoin

This material is provided by Ranbaxy UK Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan. This booklet is intended for pharmacists who are involved with dispensing Isotretinoin and it provides a guide to dispensing Isotretinoin in accordance with the Pregnancy Prevention Programme.

For Healthcare Professionals

Physician’s Guide to Prescribing Isotretinoin

This material is provided by Ranbaxy UK Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan. This booklet is intended for physicians who prescribe Isotretinoin and it provides a summary of the Pregnancy Prevention Programme.

For Healthcare Professionals

Generics UK T/A Mylan

Isotretinoin Checklist for Prescribing to Female Patients

Pregnancy Prevention Programme, Checklist for Prescribing to Female Patients

For Healthcare Professionals

Isotretinoin Contraception Brochure

Pregnancy Prevention Programme, Brochure on Contraception

Isotretinoin Patient Acknowledgement Form

Pregnancy Prevention Programme, Acknowledgement Form for Female Patients

Isotretinoin Patient Information Brochure

Pregnancy Prevention Programme, Patient Information Brochure

Isotretinoin Pharmacist's Guide

Pregnancy Prevention Programme, Pharmacist's Guide to Dispensing Isotretinoin

For Healthcare Professionals

Isotretinoin Physician's Guide

Pregnancy Prevention Programme, Physician's Guide to Prescribing Isotretinoin

For Healthcare Professionals

Izinova

Allergan Ltd

Izinova UK RMM Patient Leaflet V2

Patient Leaflet. This instruction form is provided to the patient on the day of the prescription in accordance with the risk management plan in force for this medicine.

Izinova UK RMM Physician Leaflet V2

This instruction form is provided to the healthcare professional in accordance with the risk management plan in force for this medicine.

For Healthcare Professionals